Business Wire

Planview Continues Acceleration with Record Revenue in FY’22

30.1.2023 17:00:00 EET | Business Wire | Press release

Share

Planview, the leading platform for connected work from portfolio planning to delivery, today announced record annual recurring revenue (ARR) for fiscal year 2022, continuing a trend of strong performance. Planview exceeded $380 million in total ARR for 2022, representing 17% growth year-over-year (YoY).

“It was another record year for Planview, underpinned by our commitment to build the digital future of connected work through product innovation and customer success,” said Razat Gaurav, Chief Executive Officer, Planview. “The macroeconomic uncertainties and headwinds faced by organizations today make prioritizing product and project initiatives, and thoughtfully allocating constrained resources and capital, more important than ever. Our global customer base relies on our solutions to help them achieve productivity, efficiency, and positive business outcomes from transformation initiatives across the enterprise.”

Fiscal Year-End Highlights

Planview achieved record levels for the full fiscal year 2022:

  • Total revenue surpassed $410 million for the full year
  • ARR grew by over 17% YoY to over $380M
  • Record 25% increase in monthly active users YoY for leading products
  • Customer retention rates are up 6% YoY

Strong New Logo and Customer Momentum Driven by Product Innovation

Key customer wins and expansions have driven Planview’s profitable growth. In 2022, the company added 482 net new customers. New and notable customers who selected or expanded their footprint with Planview include: Builders FirstSource, Inc., Delta Dental of California, DS Smith, Fonterra, General Motors, Maximus, Inc., Olam International Limited, Publicis, RxBenefits, Schluter, Siemens, Sysco Corporation, T-Mobile, The Emmes Company, LLC, Tetra Pak, and UiPath.

This growth was accelerated by the success of Planview’s connected platform of solutions, which helps organizations improve time-to-value, do more with the teams and resources allocated, and de-risk strategic investment decisions. Planview’s innovation over the past year continued to drive desired business outcomes for customers. Enhancements include:

  • Expanding Objective and Key Results (OKRs) capabilities, enabling access to an embedded goal framework across the enterprise
  • Introducing Time-to-Market dependency and outlier analytics, ensuring organizations can focus their investments and resources where they are most needed
  • Extending visual planning and prioritization support and card automation capabilities, centrally defining planning and delivery increments and streamline productivity across multiple teams
  • Enhancing UX/UI functionality

Additionally, the strategic acquisitions of Tasktop and Enrich in the first half of 2022 fueled Planview’s data science, planning, connectivity, and transformation offering. The Value Stream Management solution added last year, via the Tasktop acquisition, empowers organizations to accelerate their time to market, improve operational efficiency, and drive investment confidence in the face of economic disruption and instability.

Leading industry analyst firms have named Planview a leader in several key reports last year, reinforcing Planview’s leadership in Strategic Portfolio Management (SPM), Enterprise Agile Planning (EAP), Project and Portfolio Management (PPM), and Value Stream Management (VSM). Reports include:

Investing in Customer Success

To support continued customer success, training and learning were areas of strategic focus and investment. The company expanded a dedicated global learning team responsible for driving the Planview instructor-led training programs, developing new, engaging e-Learning offerings, and deploying a flagship learning management system, The University of Planview. The company also expanded its Evolve Advisory Services, supporting customers with the people and process change management that is required as part of business transformation.

To help deliver successful solutions to customers across the globe, faster, Planview also expanded its partner ecosystem, including new or expanded strategic relationships with the likes of Accenture, Atos, AWS, Deloitte, Infosys, and PwC, among others.

Planview Expands to Support Global Customer-base

Offering additional support for a more global customer base, Planview made strategic hires across its product development, customer success, sales, and marketing functions. Scaling up the company’s global operations, Planview opened a new regional office in Singapore and invested heavily in growing the company’s Global Capacity & Innovation Center in Bangalore, increasing its headcount in APAC by 65%.

To learn more about Planview, visit: www.planview.com.

About Planview

Planview has one mission: to build the future of connected work, from ideas to impact. Planview helps organizations accelerate the achievement of what matters most, supporting our customers from need to speed, from passion to progress, and from overhead to optimization. Our connected platform of solutions underpins the business and digital transformations of more than 4,500 customers globally, including 59 of the Fortune 100. Planview empowers enterprises to improve time-to-market and predictability, increase efficiency to unlock capacity, and ensure their most strategic initiatives deliver the desired business outcomes. Learn more about our portfolio at planview.com, and connect with us on LinkedIn and Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations for Planview
Natalie Reina
Director of Corp Comms
956-878-9176
natalie.reina@planview.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye